Taysha Gene Therapies annual operating margin
2022
2023
2024
2025
Taysha Gene Therapies Operating Margin Growth & History (TSHA)
Taysha Gene Therapies's operating margin was −1,130.65% for fiscal 2025.
View full Taysha Gene Therapies company overviewTaysha Gene Therapies annual operating margin history
| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −1,130.65% | −33.09 pp |
| 2024 | 2024-12-31 | −1,097.55% | −628.72 pp |
| 2023 | 2023-12-31 | −468.83% | +6023.86 pp |
| 2022 | 2022-12-31 | −6,492.69% | — |
Taysha Gene Therapies quarterly operating margin
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q4.25
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q4 2025 | 2025-12-31 | −515.95% | +932.48 pp |
| Q2 2025 | 2025-06-30 | −1,347.08% | +568.30 pp |
| Q1 2025 | 2025-03-31 | −930.54% | −217.26 pp |
| Q4 2024 | 2024-12-31 | −985.76% | −534.98 pp |
| Q3 2024 | 2024-09-30 | −1,448.43% | −1106.04 pp |
| Q2 2024 | 2024-06-30 | −1,915.38% | −939.01 pp |
| Q1 2024 | 2024-03-31 | −713.28% | −361.41 pp |
| Q4 2023 | 2023-12-31 | −450.78% | — |
| Q3 2023 | 2023-09-30 | −342.39% | — |
| Q2 2023 | 2023-06-30 | −976.37% | — |
| Q1 2023 | 2023-03-31 | −351.87% | — |
Taysha Gene Therapies operating margin trends
Across the available reported history, Taysha Gene Therapies's operating margin decreased from −1,097.55% to −1,130.65%, a change of −33.09 percentage points. The latest reported quarter, Q4 2025, shows −515.95%.
About the metric
What operating margin means
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
Calculation and source
How operating margin is calculated
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Taysha Gene Therapies filings at SEC.gov ↗